OBR Daily Commentary - Lymphoma (includes NHL, HL, CNS Lymphoma)

forumImage

U.S. Medicare Sets Outpatient Rate For Yescarta Reimbursement

(Reuters) Apr 5, 2018 - Medicare, the U.S. government healthcare program for the elderly and disabled, will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000, according to the Centers for Medicare & Medicaid Services (CMS).

Winston Wong, PharmD (Posted: April 09, 2018)

quotesCMS has set the reimbursement for their near normal outpatient rate, thus CMS is treating the CAR-T therapies as an outlier, since the normal hospital reimbursement would be based upon the DRG. Given the co-pay cap, there seems to be little margin for the institution. Need to watch can see what will happen with the additional service reimbursement request.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting

(Merck) Mar 14, 2018 - Late-breaker presentation of overall survival and progression-free survival results from pivotal phase 3 KEYNOTE-189 trial with KEYTRUDA ® (pembrolizumab) plus pemetrexed and platinum chemotherapy in first-line treatment of advanced nonsquamous non-small cell lung cancer; first-time KEYTRUDA data including recurrence-free survival from phase 3 KEYNOTE-054 Study, in collaboration with EORTC, in patients with stage III surgically resected high-risk melanoma.

H. Jack West, MD (Posted: March 15, 2018)

quotesThis presentation of data from KEYNOTE-189, CheckMate-227, IMpower150, and some other trials of immunotherapy combinations in first line advanced NSCLC will be in the same blockbuster session on late Monday morning at AACR. This two hour period will likely have a significant impact on lung cancer practice this year. All eyes interested in the field should be watching around that time.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

(BMS) Mar 6, 2018 - Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the Opdivo ® (nivolumab) dosing schedule to include 480 mg infused every four weeks (Q4W) for a majority of approved indications.

H. Jack West, MD (Posted: March 06, 2018)

quotesWith the evidence on immune checkpoint inhibitors in many cancer settings being highly comparable, practical issues like interval between treatments and cost become the leading points of differentiation. An approved four week dosing schedule will lead me to favor this for a larger proportion of my patients moving forward.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...